MedPath

Neuralis S.A.

🇨🇱Chile
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Single and Multiple Intravenous Administrations of Estetrol (E4) in Healthy Adult Volunteers

Phase 1
Terminated
Conditions
Safety
Pharmacokinetics
Interventions
Drug: single E4 28.3 mg
Drug: single E4 94.4 mg
Drug: multiple E4 94.4 mg
Drug: Placebo
First Posted Date
2022-07-15
Last Posted Date
2025-07-04
Lead Sponsor
NEURALIS s.a.
Target Recruit Count
8
Registration Number
NCT05460065
Locations
🇧🇬

MC Comac Medical Ltd, Sofia, Bulgaria

Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection

Phase 2
Conditions
Covid19
Interventions
First Posted Date
2021-03-17
Last Posted Date
2021-08-02
Lead Sponsor
NEURALIS s.a.
Target Recruit Count
162
Registration Number
NCT04801836
Locations
🇧🇪

ERASME Hospital, Brussels, Belgium

🇧🇪

CHR Citadelle, Liège, Belgium

🇭🇺

Koranyi National Institute of Pulmonology, Budapest, Hungary

and more 22 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.